Granulocyte colony-stimulating factor receptor (CSF3R) (CSF3R)

The Granulocyte colony-stimulating factor receptor (CSF3R), also known as CD114, is a type I cytokine receptor that plays a pivotal role in hematopoiesis [UniProt, NCBI]. It is primarily expressed on myeloid progenitor cells and mature neutrophils, where it mediates the effects of its ligand, G-CSF [UniProt, StatPearls]. Upon ligand binding, CSF3R undergoes homodimerization, activating intracellular signaling cascades such as the JAK/STAT, MAPK, and PI3K/AKT pathways [UniProt, StatPearls]. These pathways drive the proliferation, differentiation, and survival of cells in the granulocyte lineage, specifically leading to the production of neutrophils [UniProt, StatPearls]. Therapeutically, CSF3R is targeted by recombinant G-CSF analogs like filgrastim and pegfilgrastim to manage chemotherapy-induced neutropenia and mobilize hematopoietic stem cells for transplantation [DrugBank, StatPearls]. Beyond its role in normal physiology, gain-of-function mutations in the CSF3R gene, such as the T618I mutation, are oncogenic drivers in chronic neutrophilic leukemia and other myeloid malignancies [PubMed, NCBI]. Conversely, mutations that truncate the cytoplasmic domain of the receptor are associated with severe congenital neutropenia and a high risk of progression to acute myeloid leukemia [PubMed, NCBI]. Consequently, CSF3R is a vital target for both supportive care in oncology and as a diagnostic marker in hematologic disorders [NCBI, PubMed].

Other names

CD114G-CSFRColony stimulating factor 3 receptorGCSF Receptor

Agonism of the receptor to stimulate the production, maturation, and activation of neutrophils from hematopoietic progenitor cells [DrugBank, StatPearls].